Section of Cytopathology, University of Pisa and Pisa University Hospital, Pisa, Italy.
Thyroid. 2012 Mar;22(3):292-8. doi: 10.1089/thy.2011.0107. Epub 2011 Dec 19.
Papillary carcinomas with diameters that are less than or equal to 1 cm (thyroid papillary microcarcinoma [mPTC]) are quite common but can carry more risk than previously thought. The proper treatment and management of these lesions is still being debated. Even though fine needle aspiration cytology (FNAC) is considered the best method for the diagnosis of thyroid nodules, its efficacy is still questioned for mPTC. We investigated the role of BRAF gene status in preoperative cytological samples, using manual macrodissection as an additional tool to improve the diagnostic accuracy of mPTC.
DNA was extracted directly from stained FNAC smears of 95 patients including 85 with histological diagnoses of papillary thyroid carcinoma (PTC) ≤1 cm and 10 with goiters. The cytological diagnoses of the 95 cases included the following: 42 samples were suspicious for papillary carcinoma, 38 were PTCs, and 15 were indeterminate lesions. DNA was then extracted from the FNAC slides after performing a "manual macrodissection" procedure. The BRAF(V600E) mutational status was determined by sequence analysis in all the patients.
In this study, we showed that the BRAF(V600E) mutation was present with a high frequency in patients with mPTC (74%). The presence of the mutation was independent of the size of the tumor. In our study, the combination of the cytological diagnosis and the molecular analysis was able to identify 82% of all cases of mPTC, with an increase of 37% compared with a morphological diagnosis alone. The morpho-molecular analysis was able to reduce the number of suspicious cases by >70%. All of the goiters had a wild-type BRAF status.
The analysis of BRAF mutational status in FNAC obtained from papillary microcarcinomas demonstrates that molecular pathology, combined with morphology and molecular biology is a powerful tool for cytological diagnosis of mPTC. Our results also confirm the data supporting the biological relevance of PTCs with diameters that are ≤1 cm and the importance of "manual macrodissection" in the molecular analysis of cytological material.
直径小于或等于 1cm 的甲状腺乳头状癌(甲状腺乳头状微癌[mPTC])较为常见,但比先前认为的风险更高。这些病变的适当治疗和管理仍存在争议。尽管细针穿刺细胞学(FNAC)被认为是诊断甲状腺结节的最佳方法,但对于 mPTC 的诊断效能仍存在质疑。我们通过手动宏观解剖作为提高 mPTC 诊断准确性的附加工具,研究了 BRAF 基因突变状态在术前细胞学样本中的作用。
从 95 例患者的 FNAC 涂片(包括 85 例组织学诊断为直径≤1cm 的甲状腺乳头状癌[PTC]和 10 例甲状腺肿)中直接提取 DNA。95 例患者的细胞学诊断如下:42 例为可疑乳头状癌,38 例为 PTC,15 例为不确定病变。然后,在进行“手动宏观解剖”程序后,从 FNAC 载玻片上提取 DNA。所有患者均通过序列分析确定 BRAF(V600E)突变状态。
在本研究中,我们发现 mPTC 患者 BRAF(V600E)突变的发生率很高(74%)。该突变的存在与肿瘤的大小无关。在我们的研究中,细胞学诊断与分子分析的结合能够识别 82%的所有 mPTC 病例,与单独进行形态学诊断相比,增加了 37%。形态-分子分析能够将可疑病例的数量减少 70%以上。所有甲状腺肿均为 BRAF 野生型。
对来自甲状腺微癌的 FNAC 进行 BRAF 基因突变分析表明,分子病理学与形态学和分子生物学相结合是 mPTC 细胞学诊断的有力工具。我们的结果还证实了支持直径≤1cm 的 PTC 具有生物学相关性的数据,以及“手动宏观解剖”在细胞学标本的分子分析中的重要性。